Rapamycin is named as an intervention in 7 current clinical trials in our USA and China registers. 4 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AgelessRx (2). The most-studied condition is Aging.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia
NCT06722586 · ClinicalTrials.gov ↗ · Antiphospholipid (aPL)-Positive, Thrombocytopaenia
|
Phase 4 | Recruiting | Peking University First Hospital | China |
|
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
NCT07092618 · ClinicalTrials.gov ↗ · Longevity, GLP-1, Geroscience
|
Phase 2/3 | Recruiting | AgelessRx | USA |
|
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06528301 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL)
|
Phase 1 | Recruiting | Umoja Biopharma | USA |
|
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
NCT06743503 · ClinicalTrials.gov ↗ · Large B-cell Lymphoma
|
Phase 1 | Recruiting | Nanjing IASO Biotechnology Co., Ltd. | China |
|
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
NCT04736589 · ClinicalTrials.gov ↗ · Breast Cancer
|
Phase 3 | Not yet open | Peking Union Medical College | China |
|
Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains
NCT07436611 · ClinicalTrials.gov ↗ · Port Wine Stains
|
Phase 2 | Not yet open | AFT Pharmaceuticals, Ltd. | USA |
|
Combination Gerotherapeutic Interventions for Healthspan Improvement
NCT07475546 · Healthspan Improvement, Aging, Longevity
|
Phase 3 | Active, closed | AgelessRx | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Aging | 2 |
| Longevity | 2 |
| Healthspan Improvement | 1 |
| Port Wine Stains | 1 |
| GLP-1 | 1 |
| Geroscience | 1 |
| Lymphoma, B-Cell | 1 |
| Lymphoma, Non-Hodgkin (NHL) | 1 |
| Lymphoma, Large B-Cell, Diffuse (DLBCL) | 1 |
| Chronic Lymphocytic Leukemia (CLL) | 1 |
| Large B-cell Lymphoma | 1 |
| Breast Cancer | 1 |
| Antiphospholipid (aPL)-Positive | 1 |
| Thrombocytopaenia | 1 |
| Lead sponsor | Trials |
|---|---|
| AgelessRx | 2 |
| AFT Pharmaceuticals, Ltd. | 1 |
| Umoja Biopharma | 1 |
| Nanjing IASO Biotechnology Co., Ltd. | 1 |
| Peking Union Medical College | 1 |
| Peking University First Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 4 | 2 |
| Clinical trials in China | 3 | 2 |
A trial with sites in more than one country appears in each of those registers.
7 current trials in our USA and China registers name Rapamycin as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 7 trials are recruiting: 2 with sites in USA and 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
AgelessRx (2), AFT Pharmaceuticals, Ltd (1), Umoja Biopharma (1) and Nanjing IASO Biotechnology Co., Ltd (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rapamycin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rapamycin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rapamycin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.